Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma

Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma

Author Petrilli, A. S. Google Scholar
Kechichian, R. Google Scholar
Broniscer, A. Google Scholar
Garcia, R. J. Google Scholar
Tanaka, C. Google Scholar
Francisco, J. Google Scholar
Lederman, H. Google Scholar
Odone, V Google Scholar
Camargo, O. P. Google Scholar
Bruniera, P. Google Scholar
Pericles, P. Google Scholar
Consentino, E. Google Scholar
Ortega, J. A. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade de São Paulo (USP)
Fac Med Santa Casa São Paulo
Abstract Background. Chemotherapy has dramatically improved the rates of cure and survival of patients with localized and metastatic osteosarcoma. Nonetheless, the number of chemotherapeutic agents active against osteosarcoma is limited to doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide. Carboplatin, a cisplatin analogue, has been tested as a single agent in patients with recurrent osteosarcoma or as part of multiagent chemotherapy in newly diagnosed patients. Procedure. We tested the activity and toxicity of two cycles of intraarterial carboplatin as a window therapy (600 mg/m(2) per cycle) in 33 consecutive patients with extremity osteosarcoma before the start of multiagent chemotherapy. Response was based on clinical (tumor diameter, local inflammatory signs, and range of motion) and radiological parameters (plain local films and arteriographic studies prior to drug administration). Results. Patients' age ranged between 8 and 18 years (median age 13 years). Primarytumor originated from the femur (15 patients), tibia (10 patients), fibula (4 patients), humerus (3 patients), and calcaneus (1 patient). Only 7 patients (21%) had metastatic disease at diagnosis (5 in the lung and 2 in other bones). A favorable clinical and radiological response was documented in 81% and 73% of the patients, respectively. Clinical and radiological progression occurred in 120% and 9% of the patients, respectively. Seventeen of the patients remain alive and disease-free. Survival and event-free survival at 3 years for nonmetastatic patients are 71% (SE = 9%) and 65% (SE = 9%), respectively; for metastatic patients, the figures are 17% (SE = 15%) and 14% (SE = 13%), respectively. Conclusions. We conclude that carboplatin is an active agent in the treatment of newly diagnosed extremity osteosarcoma. (C) 1999 Wiley-Liss, Inc.
Keywords osteosarcoma
extremity tumors
carboplatin (CBDCA)
childhood cancer
Language English
Date 1999-08-01
Published in Medical and Pediatric Oncology. New York: Wiley-liss, v. 33, n. 2, p. 71-75, 1999.
ISSN 0098-1532 (Sherpa/Romeo, impact factor)
Publisher Wiley-Blackwell
Extent 71-75
Access rights Closed access
Type Article
Web of Science ID WOS:000081495500002

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account